Jazz Pharmaceuticals JAZZ EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's EPS (diluted)?
- Jazz Pharmaceuticals (JAZZ) reported EPS (diluted) of $4.43 in Q1 2026.
- How has Jazz Pharmaceuticals's EPS (diluted) changed year-over-year?
- Jazz Pharmaceuticals's EPS (diluted) increased by 391.4% year-over-year, from -$1.52 to $4.43.
- What is the long-term trend for Jazz Pharmaceuticals's EPS (diluted)?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's EPS (diluted) has grown at a 17.1% compound annual growth rate (CAGR), from -$5.42 to $8.70.
- What does EPS (diluted) mean?
- The amount of profit earned per share, assuming all potential shares that could be issued are actually issued.
- How do you interpret EPS (diluted)?
- Higher values suggest stronger earnings performance even after accounting for potential dilution; a significant gap between basic and diluted EPS highlights the impact of equity-based compensation or convertible debt.
- How does EPS (diluted) compare across companies?
- Standardized across public companies; essential for comparing firms with significant employee stock option programs.